Molecular Imaging: Page 60

Cambridge team moves ahead with multidimensional imaging

By James Tyrrell

Sarah Bohndiek, PhD, and her colleagues at the U.K.'s University of Cambridge are on a mission to develop low-cost and nonionizing optical technology to improve early cancer detection. Bohndiek heads up an international team combining physicists, engineers, chemists, and molecular biologists.

August 31, 2017

GE signs cyclotron partnership with Canadian firm

By AuntMinnieEurope.com staff writers

GE Healthcare and Canadian radioisotope production technology developer ARTMS Products have formed a strategic partnership to enhance the production and processing of radioisotopes on GE's PETtrace 800 series of medical cyclotrons.

August 28, 2017

Hybrid modalities disappoint in bone metastases accuracy

By Wayne Forrest

Despite the apparent technological advantages of SPECT/CT, PET/CT, and PET/MRI, the three hybrid modalities do not perform appreciably better than planar bone scintigraphy in detecting and diagnosing bone metastases, according to a study published online on 10 August in the Journal of Nuclear Medicine.

August 24, 2017

JAMA: PET best option to diagnose ischemic heart disease

By Wayne Forrest

A head-to-head comparison to determine the most accurate modality for diagnosing myocardial ischemia has found that PET outperforms SPECT, coronary CT angiography, and hybrid variations of the three modalities in patients with suspected coronary artery disease, according to a study published online August 16 in JAMA Cardiology.

August 20, 2017

Total-body PET scanner targets pediatric patients

By Ian Randall

A high-resolution total-body PET scanner, which will be the first of its kind in Europe, is being developed in Belgium. The machine -- dubbed PET20.0 -- will be completed by 2020, and will offer higher resolution scanning suitable for children.

August 10, 2017

Dynamic PET tracks early treatment response

By Cynthia E. Keen

For head-and-neck cancer patients, dynamic PET can provide detailed characterization of the tumor microenvironment and a more accurate assessment of response, and also may be useful for cancers exhibiting a wide range of distribution volumes.

July 30, 2017

Blue Earth secures Irish deal

By AuntMinnieEurope.com staff writers

Molecular imaging firm Blue Earth Diagnostics has signed a new manufacturing and distribution agreement with Irish firm M2i for its Axumin (fluciclovine F-18) PET agent.

July 26, 2017

BMJ: Euratom withdrawal will put patients at risk

By AuntMinnieEurope.com staff writers

New concerns have been voiced about the U.K.'s proposed withdrawal from the European Atomic Energy Community (Euratom), as part of the government's "hard" Brexit plan. This move would threaten the medical isotope supply and put patients at risk, according to an article published on 26 July in BMJ.

July 26, 2017

PET is center of attention at U.K. Alzheimer's conference

By Wayne Forrest

While PET can accurately detect or exclude Alzheimer's disease by imaging beta-amyloid plaques in the brain, the modality is underutilized in clinical care, according to research presented this week at the Alzheimer's Association International Conference in London.

July 18, 2017

Radiotherapy boost based on PET not always helpful

By Wayne Forrest

Selectively increasing radiotherapy dose in tumor areas with significant uptake of the PET radiotracer F-18 fluoromisonidazole (FMISO) does not necessarily improve outcomes for non-small cell lung cancer patients, according to a phase II study published in the July issue of the Journal of Nuclear Medicine.

July 12, 2017

RCR warns over post-Brexit radioisotope access

By AuntMinnieEurope.com staff writers

The U.K. Royal College of Radiologists (RCR) is seriously concerned about continued access to radioisotopes if the U.K. leaves the European Atomic Energy Community treaty as a result of Brexit.

July 11, 2017

AuntMinnieEurope.com Molecular Imaging Insider

By Wayne Forrest

July 10, 2017

Previous Page

Page 60 of 122

Next Page